← All trials
NCT05864534
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2024
- Primary completion
- May 31, 2026
- Completion date
- Aug 31, 2026
- First posted
- May 18, 2023
- Last posted
- Dec 22, 2023
- Enrollment
- 25
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Northwestern UniversityLead sponsor
- Agenus Inc.Collaborator
- Northwestern UniversityOverall official - principal investigator
- Northwestern UniversityReponsible party - principal investigator
- Northwestern UniversityStudy director
- CarTheraCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.